MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.36
+0.23
+4.48%
Closed 16:00 05/22 EDT
OPEN
5.24
PREV CLOSE
5.13
HIGH
5.40
LOW
5.24
VOLUME
2.11K
TURNOVER
--
52 WEEK HIGH
15.45
52 WEEK LOW
0.0045
MARKET CAP
26.97M
P/E (TTM)
-2.8714
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALIM stock price target is 14.75 with a high estimate of 18.00 and a low estimate of 12.00.

EPS

ALIM News

More
Edited Transcript of ALIM earnings conference call or presentation 30-Apr-20 1:00pm GMT
Q1 2020 Alimera Sciences Inc Earnings Call
Thomson Reuters StreetEvents · 05/11 11:25
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/03 11:38
Alimera Sciences Inc (ALIM) Q1 2020 Earnings Call Transcript
Motley Fool · 05/01 01:30
Alimera Sciences EPS beats by $0.32, beats on revenue
Alimera Sciences (NASDAQ:ALIM): Q1 GAAP EPS of -$0.24 beats by $0.32. Revenue of $14.54M (+12.8% Y/Y) beats by $0.78M. Press Release
seekingalpha · 04/30 01:27
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/29 22:25
Alimera Sciences Q1 Sales $14.535M Beat $13.760M Estimate
Alimera Sciences (NASDAQ:ALIM) reported quarterly sales of $14.535 million which beat the analyst consensus estimate of $13.760 million by 5.63 percent. This is a 12.76 percent increase over sales of $12.890 million the
Benzinga · 04/29 20:02
Alimera Sciences Announces First Quarter 2020 Financial Results and Provides Corporate Update
First Quarter and Recent Company Highlights: Consolidated Net Revenue Up 12% Compared to First Quarter 2019International Net Revenue Up 23% Compared to First Quarter 2019Net.
GlobeNewswire · 04/29 20:00
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.)
Benzinga · 04/29 12:40

Industry

Pharmaceuticals
-0.29%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About ALIM

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
More

Webull offers kinds of Alimera Sciences Inc stock information, including NASDAQ:ALIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALIM stock news, and many more online research tools to help you make informed decisions.